Sugi Predict
/ Targets
/ PLK4
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to PLK4 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
PHASE3 | UNKNOWN |
| CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer |
PHASE2 | COMPLETED |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer |
PHASE2 | COMPLETED |
| Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer |
PHASE2 | COMPLETED |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype |
PHASE2 | RECRUITING |
| Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma |
PHASE1/PHASE2 | COMPLETED |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer |
PHASE2 | RECRUITING |
| A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression |
PHASE2 | COMPLETED |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| Protein Tyrosine Kinases (PTK) in Multiple Myeloma |
PHASE2 | COMPLETED |
| Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome |
PHASE2 | WITHDRAWN |
| Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia |
PHASE2 | COMPLETED |
| Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas |
PHASE1 | COMPLETED |
| Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 |
EARLY_PHASE1 | COMPLETED |
| Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer |
nan | COMPLETED |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus |
nan | COMPLETED |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry |
nan | RECRUITING |
| Implementing Patients´ Competence in Oral Breast Cancer Therapy |
nan | UNKNOWN |
| Protein Intake and Step Reduction in Older Adults |
nan | COMPLETED |
| Impact of Weight Loss on the Human Sperm Epitranscriptome |
nan | ACTIVE_NOT_RECRUITING |
| Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation |
nan | COMPLETED |
| Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies |
nan | ENROLLING_BY_INVITATION |
Related proteins — ESM-2 sequence neighbours (a PLK4 binder may also engage these)